Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $25.5 million.

  • BridgeBio Pharma's Other Non-Current Assets rose 2577.99% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 2577.99%. This contributed to the annual value of $18.2 million for FY2024, which is 1958.01% down from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Other Non-Current Assets is $25.5 million, which was up 2577.99% from $18.1 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Other Non-Current Assets peaked at $49.8 million during Q2 2021, and registered a low of $16.6 million during Q1 2025.
  • For the 5-year period, BridgeBio Pharma's Other Non-Current Assets averaged around $25.5 million, with its median value being $20.8 million (2023).
  • In the last 5 years, BridgeBio Pharma's Other Non-Current Assets surged by 18861.13% in 2021 and then plummeted by 4121.16% in 2023.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Other Non-Current Assets stood at $33.0 million in 2021, then plummeted by 38.77% to $20.2 million in 2022, then increased by 11.87% to $22.6 million in 2023, then decreased by 19.58% to $18.2 million in 2024, then surged by 40.27% to $25.5 million in 2025.
  • Its Other Non-Current Assets was $25.5 million in Q3 2025, compared to $18.1 million in Q2 2025 and $16.6 million in Q1 2025.